G1 Therapeutics, a clinical-stage biotech developing novel therapeutics for cancer, announced terms for its IPO on Monday.
The Research Triangle Park, NC-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, G1 Therapeutics would command a fully diluted market value of $479 million.
G1 Therapeutics was founded in 2008 and it plans to list on the Nasdaq under the symbol GTHX. J.P. Morgan and Cowen & Company are the joint bookrunners on the deal. It is expected to price during the week of May 15, 2017.
